Neuraxis Inc (NRXS)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$5.96-1.81%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NRXS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on growing net sales as a key strategic priority to improve financial performance.
Stated as a priority in 5 of last 5 quarters. Revenue grew from $0.9 million in 2025-Q1 to $1.93 million in 2026-Q2, with guidance for $1.6 million in 2026-Q1. The trajectory shows delivering revenue growth consistent with management's stated priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Revenue increased to $1.93 million in 2026-Q2 from $1.61 million in 2026-Q1.”
“The Company expects net sales to be approximately $1.6 million for 2026-Q1.”
“Revenue was $968,127 in 2025-Q4, up from $811,414 in 2025-Q3.”
“Revenue was $811,414 in 2025-Q3, up from $894,086 in 2025-Q2.”
“Revenue was $894,086 in 2025-Q2, up from $895,655 in 2025-Q1.”
Continue efforts to control and reduce operating losses to improve profitability.
Stated as a priority in 5 of last 5 quarters. Operating losses increased from negative $1.74 million in 2026-Q1 to negative $2.12 million in 2026-Q2, indicating limited progress in managing operating losses despite ongoing focus.
“Operating income was negative $2.12 million in 2026-Q2.”
“Operating income was negative $1.74 million in 2026-Q1.”
“Operating income was negative $1.72 million in 2025-Q4.”
“Operating income was negative $2.10 million in 2025-Q3.”
“Operating income was negative $1.72 million in 2025-Q2.”
Preserve cash and liquidity to support operations and strategic initiatives.
Stated as a priority in 2 of last 5 quarters. The Company reported expected cash reserves of approximately $7.1 million as of 2026-Q1, with negative cash from operations in prior quarters. The trajectory shows ongoing efforts to maintain liquidity amid operating cash outflows.
“The Company expects cash and cash equivalents to be approximately $7.1 million as of March 31, 2026.”
“The Company disclosed cash from operating activities was negative $1.93 million in 2025-Q4.”
Over the trailing year it converted 0.73x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.